BR0211436A - Método e composição para tratamento de câncer - Google Patents

Método e composição para tratamento de câncer

Info

Publication number
BR0211436A
BR0211436A BR0211436-4A BR0211436A BR0211436A BR 0211436 A BR0211436 A BR 0211436A BR 0211436 A BR0211436 A BR 0211436A BR 0211436 A BR0211436 A BR 0211436A
Authority
BR
Brazil
Prior art keywords
composition
cancer treatment
provides
present
riminophenazine
Prior art date
Application number
BR0211436-4A
Other languages
English (en)
Portuguese (pt)
Inventor
David Lawson Morris
Mohammad Hossein Pourgholami
Original Assignee
Unisearch Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unisearch Ltd filed Critical Unisearch Ltd
Publication of BR0211436A publication Critical patent/BR0211436A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR0211436-4A 2001-07-17 2002-07-16 Método e composição para tratamento de câncer BR0211436A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR6443A AUPR644301A0 (en) 2001-07-17 2001-07-17 Method and composition for treatment of cancer
PCT/AU2002/000954 WO2003007957A1 (en) 2001-07-17 2002-07-16 Method and composition for treatment of cancer

Publications (1)

Publication Number Publication Date
BR0211436A true BR0211436A (pt) 2004-07-13

Family

ID=3830401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211436-4A BR0211436A (pt) 2001-07-17 2002-07-16 Método e composição para tratamento de câncer

Country Status (10)

Country Link
US (1) US20040067952A1 (enExample)
EP (1) EP1423118A4 (enExample)
JP (1) JP2004536857A (enExample)
KR (1) KR20040038984A (enExample)
CN (1) CN1551771A (enExample)
AU (1) AUPR644301A0 (enExample)
BR (1) BR0211436A (enExample)
CA (1) CA2453993A1 (enExample)
MX (1) MXPA04000518A (enExample)
WO (1) WO2003007957A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4763681B2 (ja) * 2004-03-05 2011-08-31 ベニテック インコーポレイテッド ＲＮＡｉ作用媒介物の同時デリバリーのためのマルチプロモーター発現カセット
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
KR20140051555A (ko) * 2012-10-23 2014-05-02 씨지케이바이오 주식회사 전립선암 예방 및 치료용 약학 조성물
CN103360329B (zh) * 2013-07-18 2015-11-18 中国科学院南海海洋研究所 一类吩嗪化合物及其在制备抗肿瘤药物中的应用
BR112018003232A2 (pt) * 2015-10-06 2018-09-25 Redhill Biopharma Ltd terapias de combinação para tratamento de câncer
WO2019060409A1 (en) * 2017-09-19 2019-03-28 The Cleveland Clinic Foundation INHIBITION OF CONNEXIN 46 TO TREAT A GLIOBLASTOMA AND OTHER STATES
CN119564691A (zh) * 2024-12-13 2025-03-07 首都医科大学附属北京佑安医院 氯法齐明在制备治疗癌症的药物中的应用
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3658M (fr) * 1964-02-18 1965-11-02 Michel Marie Andre Guerbet Composition huileuse pour l'injection intravasculaire.
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
EP0280741B1 (en) * 1986-08-29 1994-12-07 Kyowa Hakko Kogyo Kabushiki Kaisha Mitomycin derivatives
ZA928419B (en) * 1991-11-29 1994-03-01 Univ Pretoria Pharmaceutical substances or compositions and their use
US5763443A (en) * 1994-04-05 1998-06-09 Universiteit Van Pretoria MDR resistance treatment and novel pharmaceutically active riminophenazines
DE69528103T2 (de) * 1994-04-05 2003-05-15 Universiteit Van Pretoria, Gauteng Verwendung von Riminophenazin zur Behandlung von MDR-Resistenz
DE19843223A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
AUPP332898A0 (en) * 1998-05-04 1998-05-28 Unisearch Limited Pharmaceutical composition

Also Published As

Publication number Publication date
EP1423118A1 (en) 2004-06-02
JP2004536857A (ja) 2004-12-09
CN1551771A (zh) 2004-12-01
US20040067952A1 (en) 2004-04-08
EP1423118A4 (en) 2006-03-22
WO2003007957A1 (en) 2003-01-30
KR20040038984A (ko) 2004-05-08
CA2453993A1 (en) 2003-01-30
AUPR644301A0 (en) 2001-08-09
MXPA04000518A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ES2141128T3 (es) Combinacion de agentes anti-hormonales y moleculas de fijacion.
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BRPI0413255A (pt) uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BRPI0316438C1 (pt) uso de eritropoietina em doenças cardíacas
ID21529A (id) Metode dan komposisi untuk pengobatan dan pencegahan tumor, gangguan yang berhubungan dengan tumor dan kakeksia
BR9508245A (pt) Método para inhibir metástase de cáncer por administração oral de pectina citrica modificada solúvel
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR0109517A (pt) métodos e composições sinérgicas para tratar o cáncer
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
BR9811946A (pt) Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
WO2001066103A3 (en) Treatment of neoplasms by inhalation of carboplatin
BR0316238A (pt) Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
NO20022065L (no) Terapeutisk anvendelse
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
BR0211436A (pt) Método e composição para tratamento de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2060 DE 29/06/2010.